Progyny Inc. (PGNY)
NASDAQ: PGNYHealth CareMisc Health and Biotechnology ServicesUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
PGNY stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.11B
- P/E (TTM)
- 29.95
- Forward P/E
- 11.88
- EPS (TTM)
- $0.92
- Dividend yield
- None
- 52-week range
- 16.10 – 33.07
- Day range
- 25.81 – 28.32
- Volume / Avg
- 2.26M / 1.13M
- Beta
- —
- Shares outstanding
- 76.73M
- Next earnings
- Nov 5, 2026
52-week range
PGNY stock today
Progyny (PGNY) closed at $27.55 on Oct 7, up 6.33% (+$1.64), versus the S&P 500's 0.22% decline. Volume was 2.0x the average at 2.26M shares, a sign of unusually heavy trading. At this level, PGNY sits in the middle of its 52-week range of $16.10 to $33.07: 16.7% below the high, set on Jul 16, 2026 and 71.1% above the low.
PGNY is up 7.3% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 37.8%. At 29.9x trailing earnings, Progyny trades above the peer-group median of 18.3x. Its forward P/E of 11.9x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Progyny's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Progyny
Company profileProgyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions.
- Sector
- Health Care
- Industry
- Misc Health and Biotechnology Services
- CEO
- Mr. Peter Anevski CPA
- Headquarters
- New York, NY
- Employees
- 835
- IPO year
- 2019
- Website
- progyny.com
Analyst forecast
ForecastConsensus (12 analysts)
none
Avg. price target
$34.42+24.94%
- Strong buy 1
- Buy 9
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $0.27
Progyny peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AGLagilon health inc. | 85.70 | +2.76% | $1.44B | vs PGNY |
| VMDViemed Healthcare Inc. | 9.37 | +0.43% | $356.89M | vs PGNY |
| PARKPark Dental Partners Inc. | 20.94 | +1.26% | $99.58M | vs PGNY |
| CCELCryo-Cell International Inc. | 3.91 | +0.77% | $31.52M | vs PGNY |
| MGRXMangoceuticals Inc. | 0.4437 | -1.40% | $9.57M | vs PGNY |
| NIVFNewGenIvf Group Limited Class A | 0.106 | +7.40% | $2.89M | vs PGNY |
| SHCSotera Health Company | 17.90 | -1.92% | $5.11B | vs PGNY |
| FMSFresenius Medical Care AG ADR | 20.69 | -7.72% | $11.01B | vs PGNY |
Indexes, lists and sector
Progyny stock FAQ
What is Progyny's stock price today?
PGNY last traded at $27.55 as of Oct 7, 4:00 PM EDT, up 6.33% on the day. Prices are delayed at least 15 minutes.
When is Progyny's next earnings date?
Progyny is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $0.27.
What is PGNY's P/E ratio?
PGNY trades at a trailing P/E ratio of 29.95 and a forward P/E of 11.88, compared with a median of 18.3 for its closest peers.
Who is Progyny's CEO?
Mr. Peter Anevski CPA is the chief executive officer of Progyny Inc., which has about 835 employees.
What is the PGNY 52-week high?
The 52-week high for PGNY is $33.07 and the 52-week low is $16.10. The stock is currently 16.7% below its high.